COMPASS Pathways (CMPS) Aktievy
COMPASS Pathways plc är ett bioteknikföretag som fokuserar på mental hälsa i Storbritannien och USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
CMPS Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
COMPASS Pathways plc Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$13.33 |
| 52 veckors högsta | US$15.40 |
| 52 veckors lägsta | US$4.29 |
| Beta | 2.53 |
| 1 månads förändring | 11.74% |
| 3 månaders förändring | 12.87% |
| 1 års förändring | 189.15% |
| 3 års förändring | 48.61% |
| 5 års förändring | -58.12% |
| Förändring sedan börsintroduktionen | -54.03% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 20
CMPS: Phase 3 Durability And 2027 Launch Timeline Will Drive Upside
Analysts have adjusted the fair value estimate for COMPASS Pathways to $46.19 from $52.55, reflecting updated assumptions on the discount rate, long term margin profile, and a significantly higher future P/E multiple in light of recent price target changes and supportive research commentary across the Street. Analyst Commentary Recent Street research on COMPASS Pathways centers on the progress of COMP360 in treatment resistant depression, shifting regulatory signals, and the potential size and timing of a commercial opportunity.
Uppdatering av berättelse • Aug 06
CMPS: Phase 3 Durability And FDA Openness Balance Competitive And Execution Risks
Analysts now set the primary fair value estimate for COMPASS Pathways at $13, down from $17. This change reflects updated views on COMP360's commercial headroom compared with existing therapies, a somewhat higher discount rate, and tempered expectations for future P/E multiples, despite supportive Phase 3 data and a generally constructive regulatory backdrop for psychedelics.Seeking Alpha • Jul 28
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
Summary CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly’s move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 23
CMPS: Phase 3 Durability And Favorable FDA Stance Will Drive Upside
Analysts have raised the fair value estimate for Compass Pathways stock to $17.00 from $8.00, citing stronger confidence in COMP360's durable efficacy profile, supportive recent Phase 3 data, and a regulatory backdrop that they view as increasingly receptive to psychedelic treatments. Analyst Commentary Recent Street research on Compass Pathways highlights a mix of enthusiasm around COMP360's Phase 3 data and a more cautious undercurrent that focuses on execution, valuation, and regulatory timing.Recent updates
Uppdatering av berättelse • Aug 20
CMPS: Phase 3 Durability And 2027 Launch Timeline Will Drive Upside
Analysts have adjusted the fair value estimate for COMPASS Pathways to $46.19 from $52.55, reflecting updated assumptions on the discount rate, long term margin profile, and a significantly higher future P/E multiple in light of recent price target changes and supportive research commentary across the Street. Analyst Commentary Recent Street research on COMPASS Pathways centers on the progress of COMP360 in treatment resistant depression, shifting regulatory signals, and the potential size and timing of a commercial opportunity.Uppdatering av berättelse • Aug 06
CMPS: Phase 3 Durability And FDA Openness Balance Competitive And Execution Risks
Analysts now set the primary fair value estimate for COMPASS Pathways at $13, down from $17. This change reflects updated views on COMP360's commercial headroom compared with existing therapies, a somewhat higher discount rate, and tempered expectations for future P/E multiples, despite supportive Phase 3 data and a generally constructive regulatory backdrop for psychedelics.Seeking Alpha • Jul 28
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
Summary CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly’s move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 23
CMPS: Phase 3 Durability And Favorable FDA Stance Will Drive Upside
Analysts have raised the fair value estimate for Compass Pathways stock to $17.00 from $8.00, citing stronger confidence in COMP360's durable efficacy profile, supportive recent Phase 3 data, and a regulatory backdrop that they view as increasingly receptive to psychedelic treatments. Analyst Commentary Recent Street research on Compass Pathways highlights a mix of enthusiasm around COMP360's Phase 3 data and a more cautious undercurrent that focuses on execution, valuation, and regulatory timing.
Uppdatering av berättelse • Jul 08
CMPS: Phase 3 Durability Data Will Underpin Potential 2027 Launch Upside
The analyst price target for Compass Pathways has been raised to $24.47 from $21.92. Analysts point to supportive 26-week COMP360 durability data, a consistent safety profile, and a clearer path toward a potential 2027 approval and commercial launch as key reasons for the updated view.Ny berättelse • Apr 02
Phase III Progress And PTSD Expansion Will Reshape Long Term Psychedelic Mental Health Treatment
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Ny berättelse • Mar 19
Phase III Completion And PTSD Expansion Will Support A Durable Mental Health Franchise
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Ny berättelse • Mar 04
Phase III Trial Dependence Will Dominate Near Term While Long Term Potential Remains
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360, a psilocybin-based treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Analysartikel • Dec 08
Is COMPASS Pathways (NASDAQ:CMPS) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 07
Is COMPASS Pathways (NASDAQ:CMPS) Using Debt Sensibly?
NasdaqGS:CMPS 1 Year Share Price vs Fair Value Explore COMPASS Pathways's Fair Values from the Community and select...Seeking Alpha • Feb 28
Compass Pathways: Betting On The Future Of Psilocybin Therapy
Summary Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before needing additional capital. COMP360 shows promise in treating treatment-resistant depression and PTSD, with significant clinical trial results and potential long-term economic benefits. Regulatory hurdles and scientific doubts remain, but if Compass achieves FDA approval, its current market valuation could be deeply discounted relative to its long-term potential. Read the full article on Seeking AlphaAnalysartikel • Jan 04
Does COMPASS Pathways (NASDAQ:CMPS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 01
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Summary Compass Pathways plc obtained positive results from phase 2b study using COMP360 for treatment resistant depression patients; Primary endpoint met with statistically significant p-value of p<0.001. Top-line results from the phase 3 COMP005 study, using COMP360 for treatment-resistant depression patients, expected in Q2 of 2025. The global treatment-resistant depression treatment market size is projected to grow to $4 billion by 2033. Other indications being explored using COMP360 as a synthetic psilocybin are anorexia nervosa and post-traumatic stress disorder. Read the full article on Seeking AlphaSeeking Alpha • Aug 19
Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Summary The psychedelics sector has suffered a big blow, with the US FDA knocking back a New Drug Application for MDMA-assisted therapy. The potential for a negative FDA decision had been well-flagged by an advisory committee report in June, so the market may have already priced in the downside. Arguments that the negative FDA decision on MDMA may actually be good news for Compass Pathways plc and peers are not persuasive. The FDA decision is not the end of the road for the psychedelics sector, but Compass Pathways and peers face serious challenges regarding regulatory approval, access to capital and commercialization. The group took action to strengthen its balance sheet in 2023, but my cash burn analysis indicates that further capital injections will be needed before the end of 2025. Read the full article on Seeking AlphaSeeking Alpha • Jul 08
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Summary COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies. COMP360 showed promising results in Phase 2 trials for PTSD, with significant improvements in depression symptoms. Industry-wide regulatory uncertainties persist, highlighted by the FDA's recent decision against MDMA for PTSD. I believe CMPS is undervalued. Its substantial aggregate TAM and strategic collaborations bode well for potential FDA approval and commercialization. Read the full article on Seeking AlphaSeeking Alpha • May 23
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi discusses Compass, Cybin, Atai, and MindMed seeing improvements in their balance sheets and clinical trial data. Read the full article on Seeking AlphaSeeking Alpha • Apr 25
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Summary The US FDA is due to make a decision regarding MDMA-assisted therapy in August 2024 – this will be a critical event for the future of COMPASS Pathways. COMPASS Pathways’ share price has exhibited extreme volatility over the last year, highlighting the speculative nature of investing in the psychedelics sector. COMPASS Pathways has experienced delays with its COMP 005 clinical trial, but is confident that its COMP360 New Drug Application timeline remains unchanged. The departure of the company’s co-founders came as a surprise, and follows on from the sudden exit of the group’s CFO in late 2023. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Summary Compass Pathways plc, a biotech company based in London, is developing a psilocybin-based therapy for CNS disorders. The company's shares declined by over 80% in 2022 due to safety concerns and regulatory hurdles. Psilocybin is classified as a Schedule I substance in the U.S., posing challenges for commercial marketing in the country. Compass' COMP-360 therapy involves sessions with therapists and digital support, and has met efficacy endpoints in a Phase 2 study. There are multiple reasons to doubt the therapy can be approved, and Compass has a high cash burn, but Phase 3 data due this year may support an approval push, if positive. An interesting contrarian play, for those with a higher appetite for risk. Read the full article on Seeking AlphaAnalysartikel • Dec 06
Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Aktieägarnas avkastning
| CMPS | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -0.9% | 6.9% | -1.5% |
| 1Y | 189.2% | 45.3% | 17.9% |
Avkastning vs industri: CMPS översteg US Biotechs branschen som gav 45.3 % under det senaste året.
Avkastning vs Marknaden: CMPS översteg US marknaden som gav 17.9 % under det senaste året.
Prisvolatilitet
| CMPS volatility | |
|---|---|
| CMPS Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: CMPS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: CMPS s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2020 | 156 | Kabir Nath | compasspathways.com |
COMPASS Pathways plc är ett bioteknikföretag som fokuserar på mental hälsa i Storbritannien och USA. Bolaget utvecklar COMP360, en psilocybinbehandling, som befinner sig i klinisk fas III för behandling av behandlingsresistent depression och i klinisk fas II för behandling av posttraumatiskt stressyndrom och anorexia nervosa. Bolaget var tidigare känt som COMPASS Rx Limited och bytte namn till COMPASS Pathways plc i augusti 2020.
COMPASS Pathways plc Sammanfattning av grunderna
| CMPS grundläggande statistik | |
|---|---|
| Börsvärde | US$1.91b |
| Vinst(TTM) | -US$394.19m |
| Intäkter(TTM) | n/a |
0.0x
P/S-förhållande-4.7x
P/E-förhållandeÄr CMPS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CMPS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$0 |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$0 |
| Övriga kostnader | US$394.19m |
| Intäkter | -US$394.19m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -2.85 |
| Bruttomarginal | 0.00% |
| Nettovinstmarginal | 0.00% |
| Skuld/egenkapitalförhållande | 60.0% |
Hur har CMPS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/21 16:32 |
| Aktiekurs vid dagens slut | 2026/08/21 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
COMPASS Pathways plc bevakas av 22 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |